Biogen BIIB

NAS: BIIB | ISIN: US09062X1037 7/08/2026

207,94 USD (+0,80%)

(+0,80%) 7/08/2026

Grafiek Biogen Inc.

Grafiek Biogen Inc.

1 dag1d 0,80%
1 week1w 3,03%
1 maand1m 3,78%
3 maanden3m 7,49%
6 maanden6m 7,29%
1 jaar1j 59,13%
5 jaar5j -38,88%

Biogen Inc. in het nieuws

Toon enkel gratis nieuws

7 augustus 2026 · Biogen Completes Acquisition of RayThera Inc. · Persbericht

16 juli 2026 · Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide · Persbericht

15 juli 2026 · Biogen Appoints Michael J. Parini as Chief Legal Officer · Persbericht

14 juli 2026 · LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment · Persbericht

13 juli 2026 · FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease · Persbericht

12 juli 2026 · LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026 · Persbericht

29 juni 2026 · Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen · Persbericht

18 juni 2026 · Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. · Persbericht

4 juni 2026 · Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy · Persbericht

4 juni 2026 · EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus · Persbericht

Profiel Biogen Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe